{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:44:48Z","timestamp":1791521088648,"version":"4.3.4"},"reference-count":25,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:00:00Z","timestamp":1624924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Academia Espa\u00f1ola de Dermatolog\u00eda y Venerolog\u00eda (AEDV)","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>The purpose of this study is to propose a ranking system for the severity of psoriasis. The consensus method of selecting the indices to include and the classification of real patient profiles by an expert panel to create a gold standard of severity were used. The performance of potential cut-offs was evaluated to create a ranking algorithm. The combined use of PASI, BSA, and sPGA may allow the classification of the severity of psoriatic patients. The final algorithm identifies severe patients in a single step (2 out 3 are met: PASI \u2265 11 or BSA \u2265 10 or sPGA \u2265 3), while two steps are required for mild ((2 out 3 are met: PASI \u2264 3 or BSA \u2264 5 or sPGA \u2264 2) and DLQI &lt; 5) and moderate forms (the patient does not meet 2 out 3 (PASI \u2265 11 or BSA \u2265 10 or sPGA \u2265 3) but has a DLQI \u2265 5. A ranking algorithm is presented, consisting of different measures of disease which classifies psoriatic patients into three categories: mild, moderate, and severe.<\/jats:p>","DOI":"10.3390\/life11070627","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T04:31:07Z","timestamp":1624941067000},"page":"627","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["A New Classification of the Severity of Psoriasis: What\u2019s Moderate Psoriasis?"],"prefix":"10.3390","volume":"11","author":[{"given":"Laura","family":"Salgado-Boquete","sequence":"first","affiliation":[{"name":"Dermatology Department, Complejo Hospitalario Universitario de Pontevedra, 36003 Pontevedra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Carrascosa","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitari Germans Trias I Pujol, Universitat Aut\u00f2noma de Barcelona, IGTP, 08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1187-1341","authenticated-orcid":false,"given":"Mar","family":"Llamas-Velasco","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario de La Princesa, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0381-6174","authenticated-orcid":false,"given":"Ricardo","family":"Ruiz-Villaverde","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario San Cecilio, Instituto Biosanitario de Granada, Ibs, 18016 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"de la Cueva","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario Infanta Leonor, 28031 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6007-7320","authenticated-orcid":false,"given":"Isabel","family":"Belinch\u00f3n","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital General Universitario de Alicante-ISABIAL-UMH, 03010 Alicante, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"ref_2","first-page":"278","article-title":"Diagnosis and management of psoriasis","volume":"63","author":"Kim","year":"2017","journal-title":"Can. Fam. Physician Med. De Fam. Can."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.autrev.2014.01.008","article-title":"Diagnosis and classification of psoriasis","volume":"13","author":"Raychaudhuri","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jaad.2017.03.037","article-title":"Real-world burden of comorbidities in US patients with psoriasis","volume":"77","author":"Shah","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1067\/mjd.2000.106374","article-title":"Two considerations for patients with psoriasis and their clinicians","volume":"43","author":"Krueger","year":"2000","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archderm.143.2.239","article-title":"National Psoriasis Foundation Clinical Consensus on Disease Severity","volume":"143","author":"Pariser","year":"2007","journal-title":"Arch. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2005.06502.x","article-title":"Current severe psoriasis and the Rule of Tens","volume":"152","author":"Finlay","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e14504","DOI":"10.1111\/dth.14504","article-title":"Emerging role of anti-IL23 in the treatment of psoriasis: When humanized is very promising","volume":"33","author":"Dattola","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Iannone, L.F., Bennardo, L., Palleria, C., Roberti, R., De Sarro, C., Naturale, M.D., Dastoli, S., Donato, L., Manti, A., and Valenti, G. (2020). Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0241575"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaad.2010.11.055","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions","volume":"65","author":"Menter","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_11","first-page":"911","article-title":"Psoriasis moderada. Propuesta de definici\u00f3n","volume":"108","author":"Notario","year":"2017","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas (Engl. Ed.)"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1080\/09546634.2018.1443200","article-title":"Defining and treating moderate plaque psoriasis: A dermatologist survey","volume":"29","author":"Knuckles","year":"2018","journal-title":"J. Dermatol. Treat."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: A proposed objective target for treatment","volume":"69","author":"Coates","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_14","first-page":"2016","article-title":"Minimal disease activity for rheumatoid arthritis: A preliminary definition","volume":"32","author":"Wells","year":"2005","journal-title":"J. Rheumatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00403-016-1637-8","article-title":"The German National Program on Psoriasis Health Care 2005\u20132015: Results and experiences","volume":"308","author":"Augustin","year":"2016","journal-title":"Arch. Dermatol. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1080\/09546634.2017.1395794","article-title":"Redefining the therapeutic objective in psoriatic patients candidates for biological therapy","volume":"29","author":"Carretero","year":"2017","journal-title":"J. Dermatol. Treat."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/jdv.16104","article-title":"Belgian Psoriasis T2T Specialist Group A Belgian consensus on the definition of a treat-to-target outcome set in psoriasis management","volume":"34","author":"Grine","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","article-title":"Definition of treatment goals for moderate to severe psoriasis: A European consensus","volume":"303","author":"Mrowietz","year":"2010","journal-title":"Arch. Dermatol. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/bjd.17128","article-title":"Definition of psoriasis severity in routine clinical care: Current guidelines fail to capture the complexity of long-term psoriasis management","volume":"179","author":"Augustin","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jaad.2019.08.026","article-title":"Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council","volume":"82","author":"Strober","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1001\/jamadermatol.2014.3593","article-title":"Economic Burden of Psoriasis in the United States","volume":"151","author":"Brezinski","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/00128071-200506060-00005","article-title":"The Psychosocial Burden of Psoriasis","volume":"6","author":"Kimball","year":"2005","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archdermatol.2010.242","article-title":"Validation of Psoriasis Clinical Severity and Outcome Measures","volume":"147","author":"Jensen","year":"2010","journal-title":"Arch. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/jdv.16564","article-title":"Definition of minimal disease activity in psoriasis","volume":"35","author":"Carretero","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/art.40060","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative","volume":"69","author":"Rider","year":"2017","journal-title":"Arthritis Rheumatol."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/11\/7\/627\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:26:28Z","timestamp":1760163988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/11\/7\/627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,29]]},"references-count":25,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["life11070627"],"URL":"https:\/\/doi.org\/10.3390\/life11070627","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,29]]}}}